Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment criteria.

According to real-world data, no survival advantage was seen when comparing 3 frontline CDK4/6 inhibitor combinations in ...

T-DXd outperformed physician’s choice of chemotherapy regardless of patients’ disease burden or time to progression on prior therapy.

Morgan Stanley analyst Maxwell Skor has maintained their neutral stance on RPTX stock, giving a Hold rating yesterday.Pick the best stocks and ...